The current treatment options for chronic kidney disease in patients with type 2 diabetes is discussed by Professor Hiddo Heerspink (University Medical Center Groningen, Groningen, Netherlands). Also discussed is the mechanism of tirzepatide, a novel once-weekly medication, which has shown to improve kidney outcomes in adults with type 2 diabetes who have increased cardiovascular risk.
Professor Hiddo Heerspink presented an abstract entitled ‘Effects of Tirzepatide vs. Insulin Glargine 100 U/mL on Kidney Outcomes in Participants with Type 2 Diabetes in SURPASS-4‘ at the 82nd American Diabetes Association Scientific Session, June 3-7, 2022.
Questions:
- Why is it so important to control the progression of chronic kidney disease (CKD) in people with type 2 diabetes? (0:22)
- Despite current treatment options, what unmet needs exist in the effective management of CKD in people with type 2 diabetes? (0:59)
- What is the mechanism of action of tirzepatide, and how does this differ from currently available therapies in this indication? (1:50)
Disclosures: Hiddo Heerspink is a consultant for: AstraZeneca, Bayer, Boehringer Ingelheim, Chinook, CSL Behring, Dimerix, Eli Lilly, Janssen, NovoNordisk and Travere. Hiddo Heerspink has received grant/research support from AstraZeneca, Boehringer Ingelheim and Novo Nordisk and is a speaker’s bureau participant with AstraZeneca.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ADA 2022.
